Ionis Pharmaceuticals (Rights to 2 cardiovascular drugs) is Buildings and Property in United States that focus on APOCIII-LRx drugs business. They cover business area such as right, two cardiovascular drug, cholesterol-carry protein, certain cardiovascular disease.
-
APOCIII-LRx Drugs
-
2855 Gazelle Court
Carlsbad, CA 92010
United States
Private
righttwo cardiovascular drugcholesterol-carry proteincertain cardiovascular disease
* We use standard office opening hours in near Ionis Pharmaceuticals (Rights to 2 cardiovascular drugs)'s location as default value for unknown and outdated data. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services.
Ionis Pharmaceuticals (Rights To 2 Cardiovascular Drugs) is Buildings and Property business from United States that founded in - ( years old in ), Ionis Pharmaceuticals (Rights to 2 cardiovascular drugs) business is focusing on APOCIII-LRx Drugs.
Ionis Pharmaceuticals (Rights to 2 cardiovascular drugs) headquarter office and corporate office address is located in 2855 Gazelle Court Carlsbad, CA 92010 United States.
Ionis Pharmaceuticals (Rights to 2 cardiovascular drugs) was founded in United States.
In , Ionis Pharmaceuticals (Rights to 2 cardiovascular drugs) is currently focus on APOCIII-LRx drugs sector.
Above is snippet of Google Trends for "APOCIII-LRx drugs" term, if you have problem loading the snippet, please visit here: Google Trend.
Disclaimer: This website is not affiliated with Ionis Pharmaceuticals (Rights to 2 cardiovascular drugs), any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The data displayed is available through open government websites and public online directory. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon.
